Weekly Research Analysts’ Ratings Updates for Moleculin Biotech (MBRX)

Several brokerages have updated their recommendations and price targets on shares of Moleculin Biotech (NASDAQ: MBRX) in the last few weeks:

• 3/26/2025 – Moleculin Biotech was upgraded by analysts at StockNews.com to a “sell” rating.
• 3/25/2025 – Moleculin Biotech was upgraded by analysts at Maxim Group from a “hold” rating to a “buy” rating. They now have a $4.00 price target on the stock.
• 3/24/2025 – Moleculin Biotech had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
• 3/13/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/5/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/3/2025 – Moleculin Biotech had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
• 2/25/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/17/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/12/2025 – Moleculin Biotech was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating.
• 2/9/2025 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

Moleculin Biotech Trading Up 0.2 %

MBRX stock opened at $0.96 on Thursday. The stock has a fifty day moving average of $1.23 and a 200-day moving average of $1.94. Moleculin Biotech, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $5.91.

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.